OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
A sBLA for nogapendekin alfa inbakicept in BCG-unresponsive non–muscle-invasive bladder cancer with papillary disease was submitted to the FDA.
The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.
Linda R. Duska, MD, MPH, contextualizes updated OS and PFS2 findings from the second interim analysis of KEYNOTE-A18 in locally advanced cervical cancer.
The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission,…
Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.
Dr Pavlick discusses the investigation of RP1 plus nivolumab in patients with advanced melanoma who have received prior immune checkpoint inhibition.
Evan T. Hall, MD, MPhil, discusses the evolving evidence base surrounding ICI continuation and rechallenge strategies in the second-line treatment of metastatic renal cell carcinoma.
Suresh S. Ramalingam, MD, FACP, FASCO, presents updated overall survival data from the Phase 3 LAURA study, demonstrating that osimertinib after chemoradiotherapy provides clinically meaningful…
Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.
